➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRIFLUOPERAZINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Trifluoperazine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01765829 Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Unknown status Instituto de Salud Carlos III Phase 3 2012-11-01 The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT01765829 Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Unknown status Fundación Pública Andaluza Progreso y Salud Phase 3 2012-11-01 The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Canadian Institutes of Health Research (CIHR) N/A 2012-04-01 The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Drug Safety and Effectiveness Network, Canada N/A 2012-04-01 The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 Antipsychotics and Risk of Hyperglycemic Emergencies Completed Canadian Network for Observational Drug Effect Studies, CNODES N/A 2012-04-01 The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02600741 Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) Recruiting Janssen Scientific Affairs, LLC Phase 4 2015-07-01 The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trifluoperazine Hydrochloride

Condition Name

Condition Name for Trifluoperazine Hydrochloride
Intervention Trials
Schizophrenia 3
Bipolar Disorder 2
Psychosis Nos/Other 1
Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trifluoperazine Hydrochloride
Intervention Trials
Schizophrenia 3
Psychotic Disorders 2
Mental Disorders 2
Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trifluoperazine Hydrochloride

Trials by Country

Trials by Country for Trifluoperazine Hydrochloride
Location Trials
United States 24
Spain 9
China 1
Taiwan 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trifluoperazine Hydrochloride
Location Trials
Ohio 2
New York 2
New Hampshire 1
Oklahoma 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trifluoperazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Trifluoperazine Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trifluoperazine Hydrochloride
Clinical Trial Phase Trials
Recruiting 4
Completed 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trifluoperazine Hydrochloride

Sponsor Name

Sponsor Name for Trifluoperazine Hydrochloride
Sponsor Trials
Lindner Center of HOPE 1
Fundación Pública Andaluza Progreso y Salud 1
Kaohsiung Kai-Suan Psychiatric Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trifluoperazine Hydrochloride
Sponsor Trials
Other 10
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
Merck
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.